<a href="https://laohu8.com/S/PPCB">Propanc Biopharma</a> Secures $112,350 Convertible Loan Agreement for Working Capital Needs
Propanc Biopharma Inc. has recently finalized a new financing agreement with an investor through a securities purchase agreement effective July 25, 2025. Under this agreement, the investor has agreed to purchase a convertible promissory note from Propanc Biopharma for a principal amount of $112,350, with a purchase price of $107,000. The company plans to utilize the proceeds from this transaction for general working capital purposes. This agreement highlights Propanc's strategic efforts to secure financial support for its operations. The note includes specific default conditions, such as failure to pay principal or interest, maintain stock listings, or meet SEC reporting requirements, which could result in immediate repayment obligations. The transaction was executed under a private placement exemption from registration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021560), on July 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.